ABSTRACT Although programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) blockade has transformed treatment in several malignancies, its role in prostate cancer remains uncertain. Interest in combination therapy, tumor-microenvironment modulation, and biomarker-guided selection highlights the need to cl...
Bin Zhou, Xin-Yue Ju, Jun Wang et al.· Human Vaccines & Immunothera...· 0 citations
A potential mechanism by which HOXC9 contributes to ESCC progression via AKT/mTOR-mediated inhibition of mitochondria-dependent apoptosis and promotion of cell proliferation is identified.
Xin-Ya Yu, Ya-Jun Wang, Xin-Yue Ju et al.· Molecular and Cellular Bioch...· 0 citations
Lung cancer remains a leading cause of cancer-related mortality worldwide, and the clinical translation of chimeric antigen receptor (CAR)-based immunotherapy into solid tumors continues to be constrained by antigen heterogeneity, an immunosuppressive microenvironment, and stromal barriers that impede immune cell traff...
Fangkai He, Xing-Yu Zhu, Xiao-Lei Wang et al.· Pharmacological Research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.